We are glad to inform  that, in the last weeks, RIVOPHARM SA has acquired the 100% of shares of HOLSTEN Pharma GmbH a pharmaceutical and marketing company in Ihringen, Germany.

The acquisition is an important platform to expand RIVOPHARM’s activities into direct sales and tenders in Germany.

Piero Poli, Chief Executive Officer of Rivopharm said “Holsten Pharma  is a perfect complement to my Company  and we warmly welcome them in our team. By strengthening our expertise we are confident to provide the best solutions for patients and healthcare professionals. Together we create an excellent combination to further expand  direct sales in both  Germany and Europe and to continue Rivopharm’s international strategy.”

Rivopharm SA and Holsten Pharma GmbH have agreed not to disclose financial details of the agreement.